<DOC>
	<DOC>NCT00814216</DOC>
	<brief_summary>This study aims to study the efficacy (as measured by change in FEV1) and safety of two-week administration of oral QAV680 in the treatment of patients with asthma.`</brief_summary>
	<brief_title>Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criteria: Mild to moderate persistent asthma for at least 6 months. Exclusion criteria: Past or recent history of significant medical illness and/or lab abnormalities including but not limited to ECG abnormalities, abnormal LFT, HIV, Hep B/C, Allergic disorders, pancreatic disease, serious underlying respiratory diseases, life threatening asthma, renal disease etc Surgical and/or medical conditions which significantly effect ADME of the drug. Prior use of asthma medications (except SABA's) prior to 2 weeks of dosing Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>QAV680</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>asthma</keyword>
</DOC>